Skip to content

Validation of the GATE Software

Validation of the GATE Software for Static Visual Field Examinations

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01265628
Acronym
ValGATE
Enrollment
30
Registered
2010-12-23
Start date
2010-11-30
Completion date
Unknown
Last updated
2012-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Visual Field Defects

Brief summary

Comparison of the differential luminance sensitivity (DLS) values at each test point

Interventions

PROCEDUREperimetry

automated static perimetry with adapted GATE strategy

Sponsors

Haag-Streit AG
CollaboratorINDUSTRY
University Hospital Tuebingen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* physical, intellectual and linguistic abilities, in order to understand the test requirements * spherical ametropia max. ± 8 dpt, cylindrical ametropia max. ± 3 dpt * distant visual acuity \> 10/20 * isocoria, pupil diameter \> 3 mm

Exclusion criteria

* pregnancy, nursing * diabetic retinopathy * asthma * HIV+ or AIDS * history of epilepsy or significant psychiatric disease * medications known to effect visual field sensitivity * acute ocular infections (e.g. keratitis, conjunctivitis, uveitis) * severe dry eyes * miotic drugs * amblyopia * squint * nystagmus * albinism * keratoconus * intraocular surgery (except for uncomplicated cataract surgery) performed \< 3 month prior to screening * history or presence of macular disease and / or macular edema * relevant opacities of central refractive media (cornea, lens, vitreous body) * ocular trauma

Design outcomes

Primary

MeasureTime frameDescription
Validation of visual field data and comparison of the differential luminance sensitivity (DLS) values at each test point by applying two perimetric software versions.up to 14 dayseach participant were examined 2 times at two seperate sessions within 14 days.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026